Innovation's Rewards

Patent PowerhousesCompiled by Francesco FiondellaInstitutions that received the most license income in fiscal-year 2002Banking on InventionInstitutions which got back the highest percentage of their research spending as license income in fiscal-year 2002. Pies are proportional to the institution's research expenditures.Science by the People, for the PeopleResearch expenditures for US universities, hospitals, and institutes equaled $37 billion in fiscal year 2002; most of the money came from fede

Written byFrancesco Fiondella
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Compiled by Francesco Fiondella

Institutions that received the most license income in fiscal-year 2002

Institutions which got back the highest percentage of their research spending as license income in fiscal-year 2002. Pies are proportional to the institution's research expenditures.

Research expenditures for US universities, hospitals, and institutes equaled $37 billion in fiscal year 2002; most of the money came from federal sources.

CHI Research's primary method of calculating technology strength multiplies the number of US patents awarded to a university by the current-impact index-how frequently the university's patents of the last five years are cited by current-year patents (1.0 being the average for all universities).

Science linkage–another measure of tech strength-is based on the number of papers cited in an institution's US patents. Technically-innovative patents, the logic goes, have a higher number of references to recent scientific work.

†AUTM's survey of over 200 US and Canadian institutions ††Life sciences consists ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies